Please provide your email address to receive an email when new articles are posted on . When a patient has a cataract and glaucoma, my mindset is not “this is a cataract patient who happens to have ...

Please provide your email address to receive an email when new articles are posted on . This combined procedure provides the benefit of improving vision and decreasing IOP postoperatively, which can ...

Contraindications: The iStent inject W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior ...

Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos ...

Glaukos Corp. (NYSE: GKOS) is seeing its continued efforts to bring new and improved products to the micro-invasive glaucoma surgery (MIGS) market pay off. MIGS-related net sales for the San Clemente ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos secured a new FDA clearance for its miniaturized stent system designed for glaucoma to help drain the inner eye of built-up fluids and normalize intraocular pressure. The company had received ...

Needham expects Glaukos Corp (NYSE:GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside ...